- This event has passed.
GLP-1 Weight Loss Medications
New York & Central New Jersey IFT Panel
Targeted Opportunities for the Food and Supplement Industries
The GLP-1 medications phenomenon is expected to cover 10% of the global population and demand outpaces supply in many countries. The medically supported weight loss market is projected to reach up to $100 billion by 2030.
These weight loss and diabetes control medications should be looked at as an opportunity more than a threat to the Food Industry. This event will be a panel presentation of 4 speakers and a moderator followed by Q&A with the audience.
Meet the Moderator
Laura Rokosz, Ph.D., RDN
Pharmaceutical & Biotechnology Sectors
Read Laura Rokosz’s Bio
As our Moderator, Laura will introduce our other speakers and share her expertise as a Dietitian, offering dietary recommendations for those undergoing treatment with GLP-1 mimetics.
Dr. Laura Rokosz is a Registered Dietitian Nutritionist (RDN) with 28 years of experience in the Pharmaceutical and Biotechnology sectors.
She earned her B.S., M.S., and Ph.D. in Food Science from Rutgers University and completed her RDN internship through the Rutgers Individual Supervised Practice Pathway (ISPP) Dietetics program.
Dr. Rokosz has worked with Schering-Plough, Merck, and Pharmacopeia, contributing to research and development in drug development.
Panelist
Dr. Colette Knight, MD
Chair of Inserra Family Diabetes Institute
Read Dr. Colette Knight’s Bio
Dr. Colette Knight serves as the chair of the Inserra Family Diabetes Institute and is the division director of Endocrinology, Diabetes, and Metabolism at Hackensack University Medical Center. Additionally, she holds the position of associate professor of medicine at Hackensack Meridian School of Medicine.
Dr. Knight is devoted to assisting patients with diabetes and is focused on eliminating obstacles that hinder access to healthcare. With a wealth of experience as a clinician, educator, and researcher, she is deeply committed to community outreach and education regarding endocrine and diabetes-related conditions.
GLP Agonists: A New Era in Obesity Management
Panel Details
Dr. Knight will explore the various factors influencing obesity, highlighting the significance of understanding the risk factors, behaviors, and mechanisms that contribute to its onset.
She will address innovative treatments, including glucagon-like peptide receptor agonists (GLP-RA), for weight management, whether used independently or alongside surgical interventions.
These treatments are linked to positive outcomes, such as enhancements in dysglycemia and cardiovascular health.
Dr. Knight’s discussion will examine the relationship between metabolism and obesity, detailing the mechanisms of action and appropriate indications for these novel therapies. Furthermore, she will cover how these medications influence satiety and the nutritional and dietary support required for patients utilizing GLP-1 therapies.
Panelist
Dr. Suketu Patel, MD, Ph.D.
Global Chief Medical Officer
Havas Health Network
Read Dr. Suketu Patel’s Bio
Dr. Patel holds the position of Global Chief Medical Officer at Havas Health Network, where he is instrumental in spearheading the GLP-1 consultancy. He has effectively launched and rejuvenated a multitude of brands across a range of therapeutic domains, including nutrition, immunology, oncology, neurology, genetics, and rare diseases. Havas Health is dedicated to enhancing its partnerships with institutions and leveraging advanced data to promote effective communication in the contemporary marketplace. Through the GLP-1 consultancy, Dr. Patel and Havas Health affirm their dedication to leading in this dynamic field.
Every Brand Needs a GLP-1 Strategy
Panel Details
The ripple effect of GLP-1s across healthcare, business, & culture
Participants will acquire knowledge regarding the impact of GLP-1s, which, through their varied mechanisms of action affecting multiple peripheral body systems, can not only promote individual weight loss but also contribute to substantial weight loss at the population level.
This trend carries significant implications for a variety of related markets. GLP-1s are poised to initiate a ripple effect across three interrelated domains: healthcare (including diabetes, obesity, cardiology, neurology, hepatology, and immunology), business (such as snack foods, airlines, fashion, fitness, and restaurants), and culture (covering social events, dating, and new hobbies).
Within these domains, we propose a three-tier model to illustrate the potential influence of GLP-1s.
Panelist
Jing Zhou, Ph.D.
Sr. Manager in Nutrition, Global Scientific & Regulatory Affairs
Ingredion
Read Jing Zhou’s Bio
Dr. Jing Zhou serves as a Senior Manager in Nutrition within the Global Scientific and Regulatory Affairs division at Ingredion. She leverages her expertise in nutrition science to enhance both the existing product portfolio and innovation initiatives, thereby fostering the growth of Ingredion’s Healthful Solutions sector.
Dr. Zhou earned her Ph.D. in Nutrition Science from Purdue University, where she focused on clinical research related to human nutrition and medical devices. With a total of 14 years of experience in the field, she possesses specialized knowledge in Clinical Nutrition, dietary protein, metabolic health, sleep quality, and skeletal muscle quality, and has authored 19 research papers and abstracts. Additionally, she holds certification as a Project Management Professional.
Ingredient Solutions to Support Consumers in the Era of GLP-1 Receptor Agonists
Panel Details
This presentation will explore ingredient solutions tailored for two primary consumer groups: those utilizing GLP-1 receptor agonists and those who are not but are interested in natural methods to enhance their satiety. For the first group, it is essential to address concerns regarding potential lean body mass loss and associated side effects.
Conversely, the second group may prioritize foods and diets that promote satiety and effective weight management. Potential ingredient solutions include dietary proteins, fibers, natural sweeteners, and fat replacers, among others.
Panelist
Linda Zeitzoff MSN, CRNP, CDCES
Manager Medical Affairs – Metabolic Health
Nestlé Health Science
Read Linda Zeitzoff’s Bio
Linda Zeitzoff is a nurse practitioner and certified diabetes care and education specialist with clinical experience managing children and young adults living with diabetes and obesity. Following clinical practice, she spent 8 years in the pharmaceutical industry as a field-based educator for Novo Nordisk® where she engaged in conversations with health care providers, patients, payers and health system executives, discussing the role GLP-1 medications play in diabetes and obesity management.
Currently, Linda is a Medical Affairs Manager at Nestlé Health Science responsible for supporting the metabolic health portfolio of products through claims substantiation, health care provider strategy and education, consumer marketing and product innovation.
Nutritional Considerations in the Era of GLP-1 Medications for Weight Management
Panel Details
Insights and opportunities learned from consumers, healthcare providers, and scientific evidence
During this discussion, attendees will gain a better understanding of the adult GLP-1 user after Linda presents consumer and healthcare professional data focusing on insights learned around attitudes and behaviors, side-effects and lapse of medication use.
Learn how Nestlé Health Science leveraged the data and scientific evidence to launch glp-1nutrition.com, a new innovative web-based platform that supports the consumer with products, tools and resources during their weight management journey.
Key benefit areas to be highlighted include muscle preservation, gut health, micronutrient intake, hydration, skin and hair health and weight rebound.
Tuesday, November 19, 2024 @ 5:00 pm – 8:30 pm EST
Fees
- Members – $55
- Non-Members – $60
- Students, Unemployed, Retirees, Executive Board – $30
Schedule
- 5-6 PM Networking & Cash Bar
- 6-7:15 PM Dinner & Panel
- 7:15-8:30 PM Dessert & Networking
Menu
Salad:
- Local farm-fresh seasonal Caprese fruit salad with burrata cheese & crostini
Choice of entree:
- Pan seared Atlantic salmon basil grapefruit beurre blanc
- “Goffle Farm” Chicken scallopini sun-dried tomato, artichoke, chardonnay sauce
- Vegetarian option (Chef’s Choice)
Dessert sampler plate:
- S’mores shooter
- Mini apple cider donut
- Cheesecake bite